



Bioprospecting in the Southern Ocean and 
Antarctica 





Bioprospecting is occurring in the Southern Ocean and Antarctica.  There is no clear jurisdiction 
that currently governs bioprospecting in the Antarctic.  Treaty parties are just beginning to discuss 
bioprospecting and it possible implications at various forums but there has been no agreement to 
date that it is a problem and a response is needed.  This paper reviews the issues and options 




Bioprospecting is a relatively new activity.  Advances over the last decade in 
genomics, genetic engineering, chemical engineering, cell technology plus the 
promise of large financial returns has not only made bioprospecting possible, but 
has also fuelled interest in the activity.  Bioprospecting is now occurring all over 
the world including the Southern Ocean and Antarctica1.  
 
Bioprospecting raises a number of issues associate with ownership and benefit 
sharing wherever it is carried out2.  These issues are complicated in the Southern 
Ocean and Antarctica where territorial claims and jurisdiction is unclear. 
 
Antarctic Treaty nations are only just beginning to realize that bioprospecting 
may have legal and policy implications that could, in a worst case scenario, 
destabilize the Antarctic Treaty system.  The first tentative discussion of the 
possible implications of bioprospecting made its way onto the agenda of the 
Antarctic Consultative Meeting (ATCM) and Commission for the Conservation of 
Antarctic Marine Living Resources (CCAMLR) in 2002. 
 
1  Bioprospecting is already carried out in the Southern Ocean and Antarctica.  A Russian patent claims 
unique multifunctional agent derived from a strain of Antarctic black yeast and a US patent describes a 
multifunctional enzyme derived from krill and fish.  Other patents claim families of antifreeze polypeptides 
derived from fish and other organisms (Jabour-Green & Nicol 2003) and the food giant Unilever has a 
patent for a protein of bacteria found in the sediment of  super salty Antarctic lake (Sunday Morning Herald 
April 2003).  In December 1999 the Australian Government committed A$30 million over 5 years to 
survey the continental shelf extending from the sector of Antarctica claimed by Australia, thought to be 
motivated in part by the potential wealth of the genetic resources of this area (Gateway Antarctica 2003). 
2 “Current policy work on bioprospecting stems from concern from New Zealand scientists that foreign 
researchers were benefiting from easy access to our biological resources without benefiting New Zealand 
(Ministry of Economic Development 2003). 
                                                 
This paper reviews the emerging issues and possible options associated with the 
practice of bioprospecting in the Southern Ocean and Antarctica.  
 
What is bioprospecting? 
 
Bioprospecting is a rather emotive term conjuring up images of mining and 
pending exploitation of a mineral resource.  The process of bioprospecting is in 
fact quite similar to conventional prospecting as we know it.  Bioprospecting is 
about looking in a targeted way for a commercially valuable resource.  In the 
case of bioprospecting, the commercially valuable resource is found in the 
biochemical or genetic resources of plants, animals and microorganisms.  
Researchers often start with an end in mind and prospect biological material they 
consider is likely to result in a product that has a specific use such as a cancer or 
heart disease drug.  
 
Bioprospecting has been defined by the Ministry of Economic Development 
(2002) as the; 
 
“…examination of biological resources (eg. plants, animals, micro-
organisms) for features that may be of value for commercial development.  
These features may include chemical compounds, genes and their 
products or, in some cases, the physical properties of the material in 
question.  The main distinguishing feature from other biotechnology 
research is the concept of ‘prospecting’ – the search for biological material 
for as yet undiscovered applications.” 
 
A rich resource for bioprospectors is the marine environment. The Southern 
Ocean and Antarctica is regarded as a good area for bioprospectors as there has 
been little exploration of the natural resources of the area.  In addition, the 
extreme nature of the environments of the Antarctic (eg. coldest, highest, driest, 
windest, saltiest etc.) give rise to a special type of organism called extremophiles.  
These organisms have developed various adaptations (eg.antifreeze, cold active 
enzymes, an ability to produce polyunsaturated fatty acids etc.) to cope with 
extreme climates that are of particular interest to the bioprospector (Maloney 
2002).   
 
What is the potential for biopropsecting? 
 
Bioprospecting is an expensive business in terms of both the time and money 
needed to collect, isolate and manipulate the bioactives and then, if a useful 
product is discovered, commercialize it.  The potential returns, however, are 
enormous. Many of the world’s most successful and valuable pharmaceuticals 
have been derived from natural products.  The value of pharmaceuticals for the 
cancer market alone was estimated to be in the order of US$24 billion by 2005 
(Munro 2003)3. 
 
“A further economic opportunity in Antarctica, which is only just beginning 
to be explored, is the exploitation of genetic resources. … Some 80% of 
marine micro-organisms are yet to be described, and their first discovery 
may be in the context of a search for ways to manipulate and exploit them 
for pharmaceutical benefit.  If this work is successful, it could well become 
for many years the single most profitable economic activity of the 
Antarctic.” (Press 2002) 
 
Who is a bioprospector? 
 
It is becoming increasingly difficult to differentiate bioprospectors from scientists 
as science moves toward an applied or commercial focus4.  Funding agencies 
and governments have a growing interest in the financial returns on their 
investments and are eager to partner with private investors that not only spread 
the risk of investments but also provide expertise in the commercialization and 
marketing of a product5. 
 
Bioprospectors can range from: 
 
• scientists working on a pure science project who may unwittingly find 
themselves a bioprospector when they discover a valuable use for what 
started out as curiosity-driven research; to  
• scientists who are commissioned or employed by pharmaceutical 
companies specifically to search for bioactives that can be developed into 
useful pharmaceutical products. 
 
What is the problem? 
 
Environmental damage and reduction in stocks can be caused by large scale 
harvesting of host organisms where the bioactive is in such small concentrations 
in the natural host or the bioactive is too complex to reproduce synthetically.  
Bioactives may also be gathered from existing collections negating the need to 
3 For comparison New Zealand’s GDP was estimated to be NZ $75.4 billion in 2001. 
4 Antarctic scientists have to some extent been exempt from the need to justify their research on economic 
grounds as maintaining a presence in the Antarctic to substantiate sovereignty claims and consultative 
status in the Antarctic Treaty system has been all important.  This imperative, though still strong, has 
weakened in the post cold war era while economic imperatives have become stronger. Antarctic science is 
an expensive business and hence there is an increasing interest in its commercial application to offset the 
costs. 
5 “ Foreign investment is often a prerequisite for research, as the required funding and expertise cannot 
always be sourced in New Zealand” (Ministry of Economic Development 2003). 
                                                 
even travel to the Antarctic to collect samples making bioprospecting potentially 
an environmentally benign activity6. 
 
Although the adverse effects on the environment are acknowledged as a 
potential problem of bioprospecting in the Antarctic much of the current 
discussion has focused on legal, political and ethical issues.  These can be 
grouped under the following headings;  
 
1. ownership and benefit sharing 
2. jurisdiction 
3. free exchange of scientific observations and results  
4. ability to respond effectively. 
 
1. Ownership and Benefit Sharing 
 
Patent protection for inventions derived from biological resources is a 
relatively recent phenomenon.  Patenting living organisms was first allowed in 
the United States in 1980 (Jabour-Green & Nicol 2003)7.  There have already 
been a number of patents lodged in various countries for inventions derived 
from bioactives originating from the Southern Ocean and Antarctica (Munro 
2003). 
 
Patents are a form of an exclusive ownership right to an invention.  A patent 
gives the holder the right to prevent others from exploiting their inventions 
without their permission for a period of up to 20 years.  In return for exclusive 
ownership, the patent system requires full public disclosure when the patent 
is filed and at the expiry date of the patent the invention will become part of 
the public domain.   
 
Not every invention can be patented.  There must be a certain amount of 
novelty (newness) to the invention, it must illustrate an obvious inventive step 
and be capable of a useful application (Gateway Antarctica 2003).  
 
Inventors often lodge patent applications in order to give them a period of 
market exclusivity on their invention and allow them to recover research and 
development costs as well as make a profit on their investment.  This is 
6 For example, Landcare Research is the custodian of a national data base and collection of 
micrioorganisms on plants.  It is beginning work with a private company to search for potential bioactive 
compounds from selected mico-organisms that are held in the collection (Ministry of Economic 
Development 2003). 
7 Diamond vs Chakrabarty Charkrabarty filed patent claims for a genetically engineered bacterium that was 
capable of breaking down multiple components of crude oil.  The Supreme Court found that there were 
limits on what was patentable eg. laws of nature, physical phenomena and abstract ideas. Chakrabarty’s 
organism, however, qualified for a patent on the basis that “the patentee has produced a new bacterium 
with markedly different characteristics from that found in nature and one having the potential for 
significant utility.  His discovery is not nature’s handiwork but his own and accordingly it is patentable” 
(Jabour-Green & Dianne Nicol 2003). 
                                                 
important for industries such as the pharmaceutical industry where research 
and development costs are high and there is a significant time lag between 
discovery and the marketing of a commercial product. 
 
Patents are granted on a national basis and can only be enforced in that 
particular country.  Most patent laws provide that non-commercial research 
can be undertaken by others on a patented invention.  This “experimental use 
exemption”, however, differs from country to country and leads to some 
uncertainty for researchers as to the level of protection that they are 
guaranteed under these provisions (Jabour-Green & Nicol 2003). 
 
The problem with patenting biological resources is finding a balance between 
private and public benefit – encouraging innovation and the development of 
products for the benefit of humankind while at the same time ensuring fair and 
equitable sharing of the benefits.  There is also an ethical dimension when the 
initial biological material comes from the global commons, the Southern 
Ocean and Antarctica (owned by either all the people of the world or no-one) 




It is generally accepted that nations and indigenous people have some 
ownership rights to their country’s biological resources (UN Convention on 
Biological Diversity 1993).  The United Nations Convention on Biological 
Diversity provides the international framework governing the access to 
genetic resources, transfer of technology and fair and equitable sharing of the 
benefits derived from genetic resources8.  Not all countries, however, have 
ratified the Convention9.  Moreover, the Convention does not deal with areas 
that do not come under the jurisdiction of a particular state such as the 
Southern Ocean and Antarctica.   
 
In 2002 the Scientific Committee on Antarctic Research (SCAR) noted when 
addressing the issue of bioprospecting that “… the Convention on Biodiveristy 
does not apply to areas not under national sovereignty thus there is no clear 
over-arching authority to respond to possible pressures on Antarctic 
resources.” 
 
8 The UN Convention on Biological Diversity essentially focuses on sovereign rights of states over their 
genetic resources.  Article 15 declares that the state that is the provider of the genetic material to determine 
access to the material and requires financial mechanisms should be established to provide fair and equitable 
sharing of research and development and the benefits of commercialization.  Article 16 requires the transfer 
of technology to developing states on fair and favorable terms and Article 19 encourages the participation 
of provider states of genetic materials in the future development (Jabour-Green & Nicol 2003). 
9 As of August 2003 168 countries have signed the Convention and 187 countries are party to it.  The 
United States signed the Convention in 1993 after the ascension of President Clinton but has failed to ratify 
it (Campaign for UN Reform 2003). 
                                                 
Furthermore, the Antarctic Treaty system10 and the United Nations 
Convention on the Law of the Sea11, that together provide a framework of 
governance for the Southern Ocean and Antarctica, were agreed to long 
before the potential for biosprospecting was recognized. Hence, neither, the 
Antarctic Treaty system nor Law of the Sea provide specific guidance for 
regulating bioprospecting.   
 
The possibility of the Convention on the Conservation of Antarctic Marine 
Living Resources (CCAMLR) applying to bioprospecting has been raised by 
Chile (ATCM 2003).  The idea, however, appears to have attracted little 
support as it seems to stretch the interpretation of what has been commonly 
regarded as a “marine living” resource.  CCAMLR also offers little guidance 
on ownership and benefit sharing of genetic products.   
 
CCAMLR as it exists could, however, regulate the gathering of samples or 
bulk harvesting of host marine organisms for their genetic resource.  It could 
set total allowable harvesting (catch) and require environmental impact 
assessments and reporting in the same way as it does the Southern Ocean 
fishery (Jabour-Green & Nicol 2003).  These measures would not apply to 
parties outside CCAMLR and would face the same enforcement issues that 
are presently highlighted by the illegal toothfish industry12. 
 
The effectiveness the Madrid Protocol in regulating bioprospecting is also 
limited to environmental impact assessments of sampling and harvesting of 
terrestrial organisms and is silent on ownership and benefit sharing issues. 
 
This leaves the Southern Ocean and Antarctica in a governance vacuum 
when it comes to managing bioprospecting.  Consequently, the area is 
vulnerable to a form of bioprospecting that could result in the lock up, through 
patents, of biological resources that are developed exclusively for private 
benefit.  It also makes bioprospecting in the Southern Ocean and Antarctica 
extremely attractive to prospectors as they are not regulated and are not 





10 The Antarctic Treaty system provides the Antarctic governance framework.  It is made up of the 
Antarctic Treaty 1959, Agreed Measures for the Conservation of Antarctic Fauna and Flora 1964, the 
Convention for the Conservation of Antarctic Seals 1972, the Convention on the Conservation of Antarctic 
Marine Living Resources 1982 and the Protocol on Environmental Protection 1991 (Madrid Protocol). 
11 The United Nations Law of the Sea 1982 provides a governance framework for the world’s oceans that 
cover ocean space, environmental control, scientific research, economic and commercial activity, the 
transfer of technology and a process to settle disputes relating to ocean matters (www.un.org/depts/los). 
12 Australia has announced that it will boost the protection of its sovereign interests with fulltime armed 
patrols of the remote and ecologically sensitive southern Ocean …. There are strong links suggesting 
organized criminal involvement in toothfish poaching … (media release 17 Dec 03). 
                                                 
3. Free exchange of scientific observations and results 
  
Potentially the most significant implication of bioprospecting in the Southern 
Ocean and Antarctica is its potential to destabilize the Antarctic Treaty system 
itself.  The introduction of commercialism into science introduces new 
imperatives.  Confidentiality and secrecy become key drivers as research 
organizations and companies compete in a race to file patents.  These 
imperatives run counter to the principles on the Antarctic Treaty guaranteeing 
the freedom of scientific research and more importantly promoting the 
exchange of information on scientific programmes, scientific observations and 
results13 and scientific personnel (Department of Foreign Affairs 1986). 
 
At the June 2003 Antarctic Treaty Consultative meeting in Madrid14 SCAR 
noted; 
 
 “…that biopropospecting could raise important issues of freedom of 
scientific information if confidentiality required by commercial 
developments limited opportunities for scientific publication”. 
 
New Zealand’s approach is a cautious one; 
 
“As a Contracting party New Zealand fully accepts this important 
obligation (Article III 1(c)) of the Treaty.  It is unclear whether the 
generation of intellectual property inherent in bioprospecting can be 
reconciled with this provision of the Treaty …We do not agree that 
publication of structures of compounds arising from Antarctic organisms 
will necessarily meet New Zealand’s obligations under Article III.” (Hughes 
2002) 
 
To date discussion on the tensions between the commercialization of science 
and the Antarctic Treaty has been limited.  There appears to have been 
virtually no discussion on the type of scientific information that needs to be 
exchanged to comply with the Treaty and when such an exchange needs to 
take place.  Bioprospectors may in fact be able to comply with Article III of the 
Treaty if expectations were more clearly set out. 
 
Other implications associated with bioprospecting include states exerting their 
claim to Antarctic territory as well as claiming ownership of the biological 
resources and products derived from them15.  It also raises some interesting 
13 Article III 1(c) of the Antarctic Treaty states that “scientific observations and results from Antarctica 
shall be exchanged and made freely available”.   
14 XXVI ATCM Madrid June 2003. 
15 For example in 1999 the Australian Minister for Foreign Affairs announced that the Australian 
Government will take action to delineate the outer limit of the extended continental shelf off the Australian 
Antarctic Territory (Department of Finance and Administration 2003).  Under Article 77 of the Law of the 
Sea coastal states have exclusive rights to the natural resources of the continental shelf.  Australian’s 
actions are a strong indication that sovereignty claims and commercial aspirations amongst Treaty parties 
                                                 
logistical issues if competing bioprospecting interests are forced to compete 
for logistical support.  Countries may become reluctant to share their support 
services16 if there is no corresponding benefit sharing agreement.  A 
perception that private companies are getting a “freeride” from publicly funded 
research and facilities (eg.such as transport and base facilities) may result in 
pharmaceutical companies being required to establish their own bases and 
support facilities to carry out bioprospecting.  Facilities could be established 
close to areas rich in extremophiles (eg. Dry Valleys and Mt Erebus).  Such 
moves would run counter to the basic premise of the Antarctic Treaty of 
preserving Antarctica as a natural reserve devoted to peace and science for 
the benefit of all humankind. 
  
4. Ability to respond effectively 
  
Since the Antarctic Treaty was signed in 1959 parties have responded to new 
issues as they have emerged and before they have become real problems.  
This approach has resulted in a series of further agreements addressing 
specific issues concerning the protection of flora and fauna, seals, marine 
living resources and environmental management.  These agreements make 
up the Antarctic Treaty system.  Signatories, however, have failed to resolve 
major issues such as sovereignty and mining and have been unable to reach 
agreement on measures of liability for environmental damage17.   
 
Concerns have therefore been raised about the ability of parties to the 
Antarctic Treaty to respond to issues raised by bioprospecting in a timely and 
effective manner given that it is already occurring (Hemmings 2003).  The 
speed of the technological progress of the bioprospecting industry18 
challenges the ability of the consensual decision making process of the 
Antarctic Treaty system to respond before all benefits have been claimed by 
private interests.  Achieving consensus in a timely manner will be made more 
are alive and well.  It is interesting to note this information is located on the Department of Finance and 
Administration’s website under “commercial projects”. 
16 The United States, Italy and New Zealand share their air and sea transport to and from the Antarctic. For 
example, would the United States be prepared to transport New Zealand scientists and support personnel on 
its aircraft if they were engaged  in commercial activity that was in direct competition with American 
scientists (Hemmings 2003). 
17 The sovereignty issue was put to one side by acknowledging, but not necessarily recognizing, the various 
claims to Antarctic territory and not prejudicing their position by subsequent agreements.  Consensus could 
not be found after 8 years of negotiation on the Convention on the Regulation of Antarctic Mineral 
Resource Activity (CRAMRA).  Despite the fact that it was signed in 1988 it was never ratified.  Instead it 
was overtaken by the Madrid Protocol that included a 50 year moratorium on mining.  The annex on 
liability for environmental damage began life in CRAMRA and was transferred to article 16 of the Madrid 
Protocol and has been negotiated since 1991 with no immediate sign of agreement (Jabour-Green & Nicol 
2003). 
18 The Ministry of Economic Development predict a 5-7 year window of opportunity available for New 
Zealand to maximize possible economic benefits from the access to its own biological resources (in New 
Zealand) and the longer that it waits the more likely it will be that valuable discoveries will be made 
without benefiting New Zealand (Ministry of Economic Development 2003). 
                                                                                                                                                 
difficult by countries restating their territorial claims with renewed vigor (Press 
2002). 
 
In a working paper to the Committee on Environmental Protection in Warsaw 
in 2002 the United Kingdom challenged members by stating: 
 
“To date it has been a hallmark or aspiration of the Treaty Parties to 
regulate, or commence the process of regulation for such issues ahead of 
them becoming a commercial reality (witness the proactive approach 
taken by parties in respect of, for example CCAS and CRAMRA19).  By so 
doing, the issues, and the means of appropriately regulating them, can be 
debated without the pressures of commercial vested interests intervening.  
The UK believes that bioprospecting is a further matter on which pre-
emptive discussion and decision-making is required.  Ground-rules need 
to be put in place before this activity gains a momentum of its own. ” 
 
What are the options? 
 
In the introduction to the this paper it was stated that bioprospecting was a 
relatively new activity in the Antarctic and that tentative discussions were just 
beginning to find a place on the agendas of the various forums of the Antarctic 
Treaty.  Most of the effort to date has been directed toward issue rising. 
Recommendations have been to Antarctic Treaty parties asking for a place on 
their various agendas to discuss bioprospecting and its implications (UK 2002, 
SCAR 2002, Gateway Antarctica 2003, Jabour-Green & Nicol 2003).   
 
There is no consensus on the proposition that bioprospecting is a problem that 
needs to be addressed.  If it was decided, however, that a response was 
warranted and the Antarctic Treaty parties were capable of responding, there is 
no consensus on what that response should be or what it should be directed to 
(ie. the action of bioprospecting, ownership and benefit sharing and/or the 
exchange of scientific information).   
 
It has been suggested that United Nations Convention on Biological Diversity  
could be extended beyond the jurisdiction of individual states to include global 
commons such as the Southern Ocean and Antarctica (Gateway Antarctica 
2003).  Parties to the Convention have produced a series of more detailed 
guidance, known as the Bonn Guidelines, which cover the issues of access to 
genetic resources and information and benefit sharing. 
 
19 CCAS = Convention for the Conservation of Antarctic Seals, CRAMRA = Convention on the Regulation 
of Antarctic Mineral Resource Activity. 
 
                                                 
Antarctic Treaty parties, however, have been extremely reluctant to involve the 
United Nations in Antarctic affairs20.  It is more likely that the Convention on 
Biological Diversity and its associated guidelines would be acceptable to the 
Antarctic Treaty parties if it were to provide a model for new provisions that are 
annexed to the Antarctic Treaty system rather than extending United Nations 
governance to the Antarctic.  A Convention on Antarctic Bioprospecting could be 
developed. This option would, however, leave a significant number of countries 
outside the Antarctic Treaty unregulated and able to bioprospect at will (Day 
2003). 
 
A less comprehensive option suggested is annexing specific guidelines on 
scientific information exchange and ownership and benefit sharing to the Treaty, 
CCAMLR or the Madrid Protocol.  The downside of thise option again is its 
inability to govern parties who are not signatories to the Antarctic Treaty. 
 
In the past Treaty parties have been able to neatly side step difficult issues by 
setting them aside (sovereignty claims) or putting in place a moratorium (mineral 
exploitation).  Bioprospecting, however, does not lend itself to this type of 
approach as it is already occurring and gathering momentum.  A moratorium 
would also be extremely difficult to enforce as the experience of stopping illegal 
toothfish fishing has shown.  A moratorium on filing patents with Treaty nations 
from bioactives derived from the Southern Ocean and Antarctica may be an 
option but once again this option leaves non-signatories to the Antarctic Treaty 
unrestrained.  Under this option the incentive to bioprospect for private benefit is  
likely to be reduced to such an extent that little or no bioprospecting takes place 
and the benefits to the world of pharmaceuticals derived from Antarctic 




Bioprospecting is a new activity.  Efforts to date have been focused on raising the 
issue and its possible implications amongst Treaty parties.   
 
As yet there is no consensus amongst Treaty parties that bioprospecting is a 
problem and that some kind of response is warranted.  There have been only 
tentative discussions on what kind of response would be effective.  If a response 
was called for, the suggestion of using the United Nations Convention on 
Biological Diversity as a model to develop a Convention on Antarctic 
Bioprospecting seems to hold the most promise.  However, this would not 
restrain non-signatories to the Antarctic Treaty. 
 
20 “Antarctic Treaty Parties fundamental belief that the UN, albeit capable of serving as a useful tool of 
government policy, should be kept firmly in its place and allow them to get on with their Antarctic 
responsibilities……no advance on the UN’s present role was favored (by Antarctic Treaty parties).” (Beck 
2003) 
                                                 
The real challenge, however, is a commitment amongst Treaty parties to the 
Antarctic Treaty system itself.  Bioprospecting raises issues of ownership, private 
benefit and the free exchange of scientific information that run counter to the 
principles of the Antarctic Treaty.  New Zealand is taking a cautious approach 
and is prepared to forgo significant economic benefits to the country in order to 
fulfill what it sees as its Treaty obligations.  Will other countries be prepared to do 
the same? 
 
The rapid growth of bioprospecting in the Southern Ocean and Antarctica will 
also challenge the ability of the consensual decision-making processes of the 
Antarctic Treaty system to respond in a timely and effective manner.  An 
alternative decision-making framework may be required in order to allow Treaty 
parties to respond more quickly to emerging issues such as bioprospecting.  A 
danger of this approach, however, would be to undermine the basis of the 
Antarctic Treaty itself and last fifty years of Treaty agreements. 
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